| DR. REDDY'S LABORATORIES LIMITED Patent applications |
| Patent application number | Title | Published |
|---|
| 20120041029 | COMPOSITIONS FOR DRUG DELIVERY - Substantially non-porous polymeric microparticles comprising a hydrophobic polymer and a plasticizer, and containing therein a bioactive or bioinactive agent. | 02-16-2012 |
| 20110287097 | PHARMACEUTICAL COMPOSITIONS COMPRISING ROPINIROLE - Controlled release pharmaceutical compositions comprising ropinirole or pharmaceutically acceptable salts thereof, wherein embodiments have ropinirole embedded in a matrix comprising one or more polymers, and the composition in monolithic form or in multiparticulate form. | 11-24-2011 |
| 20110177161 | PHARMACEUTICAL COMPOSITIONS OF [5(S)-(2'-HYDROXYETHOXY)-20(S)-CAMPTOTHECIN - There is provided a powder composition for use in a pharmaceutical product, the composition including a) 5(S)-(2′-hydroxyethoxy)-20(S)-CPT; at least one cyclodextrin; wherein 5(S)-(2′-hydroxyethoxy)-20(S)-CPT includes less than 5% of 5(R)-(2′-hydroxyethoxy)-20(S)-CPT. Preferably, in the powder composition, 5(S)-(2′-hydroxyethoxy)-20(S)-CPT is substantially free from said 5(R)-(2′-hydroxyethoxy)-20(S)-CPT. | 07-21-2011 |
| 20110094321 | PREPARATION OF APREPITANT - A process for preparing aprepitant. | 04-28-2011 |
| 20110077281 | Formulations Comprising Triptain Compounds - The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides T | 03-31-2011 |
| 20100292473 | PROCESS FOR PREPARING (2R,3S/2S,3R)-2-(2,4-DIFLUOROPHENYL)-3-(5-FLUOROPYRIMIDIN-4-YL)-1-(1H-1,2- ,4-TRIAZOL-1-YL)BUTAN-2-OL - Voriconazole is prepared by a process comprising condensing 1-(2,4-difluorophenyl)-2-(1H-1,2,4-triazole-1-yl)ethanone with 4-chloro-6-ethyl-5-fluoropyrimidine, in a ketone, ether, aliphatic hydrocarbon, or aromatic hydrocarbon solvent, to give (2R,3S/2S,3R)-3-(4-chloro-5-fluoropyrimidin-6-yl)-2-(2,4-diflurophenyl)-1-(1H-1,2,4-triazole-1-yl)butan-2-ol. | 11-18-2010 |
| 20100226597 | BORTEZOMIB AND PROCESS FOR PRODUCING SAME - The present application provides a process for the preparation of Bortezomib, its intermediates and process for crystalline forms of Bortezomib. | 09-09-2010 |
| 20100197944 | DOCETAXEL PROCESS AND POLYMORPHS - Processes for preparing substantially pure docetaxel, new crystalline forms of docetaxel and processes for preparation thereof, processes for preparing docetaxel trihydrate, and pharmaceutical compositions comprising docetaxel. | 08-05-2010 |
| 20100196464 | ORLISTAT PHARMACEUTICAL FORMULATIONS - Solid pharmaceutical formulations are prepared using compositions comprising orlistat and having average particle sizes less than about 250 μm. | 08-05-2010 |
| 20100081809 | AMORPHOUS VALGANCICLOVIR HYDROCHLORIDE - The present application relates to amorphous forms of valganciclovir salts such as the hydrochloride and processes for their preparation. | 04-01-2010 |
| 20100068269 | TREATMENT AND PREVENTION OF CARDIOVASCULAR EVENTS - A pharmaceutical dosage form for treating or preventing cardiovascular events comprises therapeutic amounts of: a β-adrenergic receptor antagonist, a diuretic, or both; a cholesterol-lowering agent; an inhibitor of the renin-angiotensin system; and aspirin. | 03-18-2010 |
| 20100063291 | PROCESS FOR PREPARATION OF SOLID MONTELUKAST - A process for preparation of montelukast or a salt thereof is provided, the process including reacting a late intermediate compound which is 2-[1-[1-R-3-[2-(7 chloro quinolin-2-yl)vinyl [phenyl]-3-[2-methoxy carbonyl phenyl]propyl sulfonyl methyl]cyclo propyl]acetic acid or a salt thereof with methyl magnesium chloride or methyl magnesium bromide in an organic solvent. In one embodiment, the process includes reacting an earlier intermediate compound which is methyl 2-(3-R-(3-(2-(7-chloro 2-quinolinyl)-ethenyl)-3 hydroxy propyl)benzoate with methane sulfonyl chloride or toluene sulfonyl chloride to obtain a mesylated or tosylated derivative of the earlier intermediate compound; followed by a reaction of the mesylated or tosylated derivative with 1-mercapto methyl cyclopropane acetic acid in a polar solvent in a presence of a base to obtain the late intermediate compound. | 03-11-2010 |
| 20100016606 | PREPARATION OF AMORPHOUS HYDROUS ESOMEPRAZOLE MAGNESIUM - A hydrate of esomeprazole magnesium in the form of an amorphous solid is provided. Methods of preparation and use of, as well as formulation containing the hydrate of esomeprazole magnesium in the form of an amorphous solid are also provided. | 01-21-2010 |
| 20090324728 | PHARMACEUTICAL COMPOSITIONS COMPRISING AMORPHOUS BENZIMIDAZOLE COMPOUNDS - Compositions comprising amorphous substituted benzimidazole compounds. | 12-31-2009 |
| 20090137605 | POLYMORPHIC FORMS OF ZIPRASIDONEAND ITS HYDROCHLORIDE SALT AND PROCESS FOR PREPARATION THEREOF - The present invention is related to crystalline forms of ziprasidone and its hydrochloride salt and an amorphous form of ziprasidone hydrochloride and the process for the preparation thereof. The crystalline forms and amorphous form of the invention are suitable for pharmaceutical purposes in the treatment of psychosis. The processes of the invention are simple, non-hazardous and commercially suitable. | 05-28-2009 |
| 20090099359 | ESZOPICLONE PROCESS - Eszopiclone is prepared by reacting zopiclone with an enatiomerically pure di-p-toluoyl tartaric acid, recovering a solid salt, and reacting a solid salt with a base. Zopiclone is prepared by reacting 6-(5-chloropyrid-2-yl)-5-hydroxy-7-oxo-5,6-dihydropyrrolo[3,4-b]-pyrazine with 1-chlorocarbonyl-4-methylpiperazine hydrochloride. | 04-16-2009 |
| 20090047354 | PROCESS FOR THE PREPARATION OF 5-(2-(4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL) ETHYL)-6-CHLORO-1, 3-DIHYDRO-2H-INDOL-2-ONE HYDROCHLORIDE (ZIPRASIDONE HYDROCHLORIDE) AND ITS INTERMEDIATE - The present invention relates to improved processes for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one and its hydrochloride, which is known as Ziprasidone hydrochloride of Formula (I) and 5-(2-Chloro acetyl)-6-chloro oxindole of Formula (IV), which is an intermediate for the preparation of 5-(2-chloro ethyl)-6-chloro oxindole of Formula (V). Ziprasidone hydrochloride of Formula (I) of the present invention is depicted by the following structure. | 02-19-2009 |
| 20080260785 | PAROXETINE COMPOSITIONS - The invention relates to pharmaceutical compositions having polymers that release paroxetine in a controlled manner for a prolonged or sustained period of time. An embodiment of the invention provides enhanced bioavailability controlled release pharmaceutical compositions comprising paroxetine or its pharmaceutically acceptable salts, which enables a reduction in its orally administered dose. | 10-23-2008 |
| 20080255366 | Crystalline Trihydrate of Zoledronic Acid - Zoledronic acid trihydrate, processes for its preparation, and conversion into zoledronic acid monohydrate. | 10-16-2008 |
| 20080226742 | Compositions for Drug Delivery - Substantially non-porous polymeric microparticles comprising a hydrophobic polymer and a plasticizer, and containing therein a bioactive or bioinactive agent. | 09-18-2008 |
